It’s too bad the 60 patients who used Leronlimab

It’s too bad the 60 patients who used Leronlimab under the EIND could not count against the Cd12 study. The profile of the patients were the same. If they had been counted against the study we would have been at our critical number by now..so there probably were ways the government could have bent some of the rules a bit to accommodate a Pandemic. That being said. Since the pandemic is still very young, there probably weren’t many drugs in the pipeline which would have been effective. Big Pharma reviewed their drug portfolios , both approved drugs and younger experimental drugs in their pipeline early on to see what might be effective but they found very little to start with..